Avadel Pharmaceuticals PLC. (NASDAQ:AVDL - Get Free Report)'s stock price crossed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $11.36 and traded as high as $18.41. Avadel Pharmaceuticals shares last traded at $17.87, with a volume of 6,775,137 shares traded.
Wall Street Analyst Weigh In
Several research firms have recently issued reports on AVDL. Wall Street Zen raised Avadel Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Sunday, September 28th. UBS Group lifted their price target on Avadel Pharmaceuticals from $13.00 to $20.00 and gave the stock a "buy" rating in a research note on Thursday, August 21st. Zacks Research downgraded Avadel Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, October 7th. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Avadel Pharmaceuticals in a research note on Wednesday, October 8th. Finally, Deutsche Bank Aktiengesellschaft reiterated a "buy" rating on shares of Avadel Pharmaceuticals in a research report on Friday, August 8th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $20.86.
Read Our Latest Research Report on Avadel Pharmaceuticals
Avadel Pharmaceuticals Stock Performance
The stock has a market cap of $1.74 billion, a PE ratio of -595.67 and a beta of 1.46. The business has a 50-day moving average of $15.02 and a 200 day moving average of $11.36.
Avadel Pharmaceuticals (NASDAQ:AVDL - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The company reported $0.10 EPS for the quarter, topping analysts' consensus estimates of $0.02 by $0.08. The firm had revenue of $68.13 million during the quarter, compared to analysts' expectations of $60.28 million. Avadel Pharmaceuticals had a negative return on equity of 3.73% and a negative net margin of 1.32%.The firm's quarterly revenue was up 64.1% compared to the same quarter last year. During the same quarter last year, the business posted ($0.14) EPS. Avadel Pharmaceuticals has set its FY 2025 guidance at EPS. Equities analysts expect that Avadel Pharmaceuticals PLC. will post -0.51 EPS for the current fiscal year.
Institutional Trading of Avadel Pharmaceuticals
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Edge Wealth Management LLC grew its holdings in Avadel Pharmaceuticals by 20.0% in the 3rd quarter. Edge Wealth Management LLC now owns 30,000 shares of the company's stock valued at $458,000 after buying an additional 5,000 shares during the period. Tower Research Capital LLC TRC grew its holdings in Avadel Pharmaceuticals by 217.5% in the 2nd quarter. Tower Research Capital LLC TRC now owns 8,795 shares of the company's stock valued at $78,000 after buying an additional 6,025 shares during the period. Krensavage Asset Management LLC grew its holdings in Avadel Pharmaceuticals by 0.9% in the 2nd quarter. Krensavage Asset Management LLC now owns 958,877 shares of the company's stock valued at $8,486,000 after buying an additional 8,877 shares during the period. MML Investors Services LLC grew its holdings in shares of Avadel Pharmaceuticals by 6.7% during the 2nd quarter. MML Investors Services LLC now owns 207,378 shares of the company's stock worth $1,835,000 after purchasing an additional 13,072 shares during the period. Finally, Man Group plc grew its holdings in shares of Avadel Pharmaceuticals by 101.3% during the 2nd quarter. Man Group plc now owns 57,931 shares of the company's stock worth $513,000 after purchasing an additional 29,149 shares during the period. Hedge funds and other institutional investors own 69.19% of the company's stock.
Avadel Pharmaceuticals Company Profile
(
Get Free Report)
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Avadel Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Avadel Pharmaceuticals wasn't on the list.
While Avadel Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
